Suppression of the clinical and cytokine response to endotoxin by RWJ-67657, a p38 mitogen-activated protein-kinase inhibitor, in healthy human volunteers

Clinical and Experimental Immunology

Volumn 124, Issue 1, 2001, Pages 16-20

  Fijen, J W ^a   Zijlstra, J G ^a   De Boer, P ^b   Spanjersberg, R ^a   Cohen Tervaert, J W ^a   Van der Werf, T S ^a   Ligtenberg, J J M ^a   Tulleken, J E ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Cytokines; Endotoxin; p38 MAPK inhibition; Sepsis

Indexed keywords

4 [4 (4 FLUOROPHENYL) 1 (3 PHENYLPROPYL) 5 (4 PYRIDINYL) 1H IMIDAZOL 2 YL] 3 BUTYN 1 OL; CYTOKINE; ENDOTOXIN; IMIDAZOLE DERIVATIVE; INTERLEUKIN 6; INTERLEUKIN 8; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; BLOOD PRESSURE; BODY TEMPERATURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DOSE RESPONSE; DRUG EFFECT; HEART RATE; HUMAN; HUMAN EXPERIMENT; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; SEPSIS;

ADULT; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTOXEMIA; ENDOTOXINS; ENZYME INHIBITORS; FEVER; HUMANS; HYPOTENSION; IMIDAZOLES; INTERLEUKIN-6; INTERLEUKIN-8; MALE; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PYRIDINES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0035000643     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.2001.01485.x     Document Type: Article

References (27)

1. 1 Wheeler AP, Bernard GR. Treating patients with severe sepsis. N Engl J Med 1999; 340:207-14.
2. 2 Adrie C, Pinsky MR. The inflammatory balance in human sepsis. Intensive Care Med 2000; 26:364-75.
3. 3 Abraham E. Why immunomodulatory therapies have not worked in sepsis. Intensive Care Med 1999; 25:556-66.
4. 4 Opal SM, DePalo VA. Anti-inflammatory cytokines. Chest 2000; 117:1162-72.
5. 5 Oberholzer A, Oberholzer C, Moldawer LL. Cytokine signaling - regulation of the immune response in normal and critically ill states. Crit Care Med 2000; 28:N3-12.
6. 6 Han J, Ulevitch RJ. Emerging targets for anti-inflammatory therapy. Nat Cell Biol 1999; 1:E39-E40.
7. 7 Nick JA, Young SK, Brown KK et al. Role of p38 mitogen-activated protein kinase in a murine modēl of pulmonary inflammation. J Immunol 2000; 164:2151-9.
8. 8 Obata T, Brown GE, Yaffe MBMAP. kinase pathways activated by stress: the p38 MAPK pathway. Crit Care Med 2000; 28:N67-N77.
9. 9 Nick JA, Avdi NJ, Gerwins P, Johnson GL, Worthen GS. Activation of a p38 mitogen-activated protein kinase in human neutrophils by lipopolysaccharide. J Immunol 1996; 156:4867-75.
10. 10 Lee JC, Laydon JT, McDonnell PC et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 1994; 372:739-46.
11. 11 Fearns C, Kline L, Gram H et al. Coordinate activation of endogenous p38alpha, beta, gamma, and delta by inflammatory stimuli. J Leukoc Biol 2000; 67:705-11.
12. 12 Raingeaud J, Gupta S, Rogers JS et al. Pro-inflammatory cytokines and environmental stress cause p38 mitogen- activated protein kinase activation by dual phosphorylation on tyrosine and threonine. J Biol Chem 1995; 270:7420-6.
13. 13 Jiang Y, Chen C, Li Z et al. Characterization of the structure and function of a new mitogen-activated protein kinase (p38beta). J Biol Chem 1996; 271:17920-6.
14. 14 Kotlyarov A, Neininger A, Schubert C et al. MAPKAP kinase 2 is essential for LPS-induced TNF-alpha biosynthesis. Nat Cell Biol 1999; 1:94-7.
15. 15 Cobb MH, Goldsmith EJ. How MAP kinases are regulated. J Biol Chem 1995; 270:14843-6.
16. 16 Suzuki K, Hino M, Hato F, Tatsumi N, Kitagawa S. Cytokine-specific activation of distinct mitogen-activated protein kinase subtype cascades in human neutrophils stimulated by granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor and tumor necrosis factor-alpha. Blood 1999; 93:341-9.
17. 17 Hale KK, Trollinger D, Rihanek M, Manthey CL. Differential expression and activation of p38 mitogen-activated protein kinase alpha, beta, gamma, and delta in inflammatory cell lineages. J Immunol 1999; 162:4246-52.
18. 18 Nick JA, Avdi NJ, Young SK et al. Selective activation and functional significance of p38alpha mitogen- activated protein kinase in lipopolysaccharide-stimulated neutrophils. J Clin Invest 1999; 103:851-8.
19. 19 Nick JA, Avdi NJ, Young SK et al. An intracellular signaling pathway linking lipopolysaccharide stimulation to cellular responses of the human neutrophil: the p38 MAP kinase cascade and its functional significance. Chest 1999; 116:54S-5S.
20. 20 Beyaert R, Cuenda A, Vanden Berghe W et al. The p38/RK mitogen-activated protein kinase pathway regulates interleukin-6 synthesis response to tumor necrosis factor. EMBO J 1996; 15:1914-23.
21. 21 Marie C, Roman-Roman S, Rawadi G. Involvement of mitogen-activated protein kinase pathways in interleukin- 8 production by human monocytes and polymorphonuclear cells stimulated with lipopolysaccharide or Mycoplasma fermentans membrane lipoproteins. Infect Immun 1999; 67:688-93.
22. 22 Wadsworth SA, Cavender DE, Beers SA et al. RWJ 67657, a potent, orally active inhibitor of p38 mitogen-activated protein kinase. J Pharmacol Exp Ther 1999; 291:680-7.
23. 23 Henry JR, Rupert KC, Dodd JH et al. 6-Amino-2-(4-fluorophenyl) -4-methoxy-3-(4-pyridyl) -1H-pyrrolo[2, 3- b]pyridine (RWJ 68354): a potent and selective p38 kinase inhibitor. J Med Chem 1998; 41:4196-8.
24. 24 Fijen JW, Muller Kobold AC, De Boer P et al. Leukocyte activation and cytokine production during experimental human endotoxemia. Eur J Int Med 2000; 11:89-95.
25. 25 van der Poll T, De Waal Malefyt R, Coyle SM, Lowry SF. Antiinflammatory cytokine responses during clinical sepsis and experimental endotoxemia: sequential measurement of plasma soluble interleukin (IL)-1 receptor type II, IL10, an IL13. J Infect Dis 1997; 175:118-22.
26. 26 Moreland LW, Baumgartner SW, Schiff MH et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997; 337:141-7.
27. 27 Badger AM, Griswold DE, Kapadia R et al. Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis. Arthritis Rheum 2000; 43:175-83.